Cengent Therapeutics Signs Genes-To-Leads Drug Discovery Contract With Dynamis Therapeutics
10/19/2005 5:12:11 PM
Cengent Therapeutics, a structure-guided drug discovery company, announced today the signing of a Genes-To-Leads(R) drug discovery contract with Dynamis Therapeutics, Inc., a Pennsylvania based biotechnology company. Under the agreement, Cengent will apply its proprietary platform lead identification technology, Genes To Leads(R), to screen for drug candidates against diabetic related kidney and heart disease, blindness and neuropathy. The proprietary drug target of Dynamis Therapeutics, Inc. is an enzyme that causes the formation of 3-deoxyglucosone. 3-deoxyglucosone is an adversely reactive molecule that causes the formation of free radicals and AGEs, Diabetics suffering from blindness and kidney disease have elevated levels regardless of glucose levels or caloric intake. The agreement includes up-front and milestone payments.
comments powered by